GYRE THERAPEUTICS, INC.
GYRE evidence brief
What we can confirm
- BioSniper Score:
- 7.4 / 10
- Market Cap:
- $725.3M
- Lead Asset:
- avatrombopag (Approved)
What it means
What to watch
Prepared research question
What matters most for GYRE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GYRE
GYRE THERAPEUTICS is a commercial-stage biopharmaceutical company focused on small-molecule therapies for organ fibrosis and inflammatory diseases, operating through a Chinese subsidiary and a U.S. headquarters, and recently acquired Cullgen to expand into targeted protein degradation.
Key risk: Clinical trial uncertainties
BioSniper Score
Based on 4 of 6 signals
Market Cap
$725.3M
Cash Runway
—
Lead Asset
avatrombopag (Approved)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 10 pipeline candidates for GYRE THERAPEUTICS, INC..
GYRE THERAPEUTICS is a commercial-stage biopharmaceutical company focused on small-molecule therapies for organ fibrosis and inflammatory diseases, operating through a Chinese subsidiary and a U.S. headquarters, and recently acquired Cullgen to expand into targeted protein degradation.
- Cash & equivalents of $43.3M as of 2026-06-30 [sec]
- Total revenue of $29.1M and net income of -$14.3M as of 2026-06-30 [sec]
- Acquired Cullgen in May 2026 in an all-stock transaction valued at approximately $300M [news]
- NDA for F351 (hydronidone) for CHB-associated liver fibrosis submitted to China's CDE in March 2026 [news]
- First patient enrolled in Phase 2/3 trial of ETUARY for radiation-induced lung injury [news]
What works
- Commercial-stage company with approved product ETUARY (pirfenidone) generating revenue in the PRC [sec_mda · as of 2026-05-08]
- Completed acquisition of Cullgen, adding a pipeline of targeted protein degrader therapies for pain, cancer, and inflammatory diseases [sec · filed 2026-04-27]
- Company projects ~$400-600 million in potential revenues within 5 years for liver fibrosis with F351 [sec · filed 2026-03-12]
- Existing cash and cash equivalents, cash flows from operations, and access to capital markets expected to fund operations for at least 12 months [sec_mda · as of 2026-03-13]
What to weigh
- Net loss of $14.3M for the period ending 2026-06-30 [sec]
- Accumulated deficit of $68.4M as of December 31, 2025 [sec_mda · as of 2026-03-13]
- Reliance on forward-looking statements with risks including ability to conduct clinical trials and obtain regulatory approvals [sec · filed 2026-07-13]
- ETUARY revenue for lung fibrosis may sustain at ~$100M only if no competitor markets a generic drug in the near-term [sec · filed 2026-03-12]
From the filings
Quoted directly from source documents.
Acquisition of Cullgen in May 2026
“In May 2026, we acquired Cullgen Inc.”
SEC MD&A · August 7, 2026
NDA submission for F351 in March 2026
“NDA for F351 (hydronidone) for CHB-associated liver fibrosis submitted to China’s CDE in March 2026”
News · May 7, 2026
Accumulated deficit of $68.4M as of December 31, 2025
“accumulated deficit of $68.4 million”
SEC MD&A · March 13, 2026
Risks & what to watch (4)›
Key risks
- Clinical trial uncertainties — Ability to conduct extensive clinical trials to demonstrate safety and efficacy of product candidates is a key risk [sec · filed 2026-07-13]
- Regulatory approval delays — Timing and likelihood of U.S., PRC, and foreign regulatory filings and approvals for F351 and other candidates are uncertain [sec · filed 2026-07-13]
- Generic competition for ETUARY — ETUARY revenue for lung fibrosis may sustain at ~$100M only if no competitor markets a generic drug in the near-term [sec · filed 2026-03-12]
- Accumulated deficit — Accumulated deficit of $68.4M as of December 31, 2025 indicates historical net losses [sec_mda · as of 2026-03-13]
What to watch
- Regulatory decision on NDA for F351 for CHB-associated liver fibrosis in China [news]
- Progress of Phase 2/3 trial of ETUARY for radiation-induced lung injury [news]
- Integration and pipeline advancement from Cullgen acquisition [sec · filed 2026-04-27]
- Full year 2026 revenue guidance of $100.5 to $111.0 million [news]
Sources: News · SEC filings · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run GYRE THERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available GYRE THERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.32 · 0% dilution
Lead: Approved
10 candidates
No upcoming catalysts tracked
0 buys · 18 sells (180d)
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
56
Total value held
$23.7M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 984,204 | $6.9M |
| blackrock, inc. | 758,630 | $5.3M |
| geode capital management, llc | 431,414 | $3.0M |
| state street corp | 216,326 | $1.5M |
| sbi securities co., ltd. | 170,837 | $1.2M |
| charles schwab investment management inc | 165,238 | $1.2M |
| vanguard fiduciary trust co | 137,682 | $960K |
| northern trust corp | 133,841 | $933K |
| goldman sachs group inc | 73,122 | $510K |
| vanguard portfolio management llc | 69,814 | $487K |
Showing top 10 of 56 institutional holders of GYRE THERAPEUTICS, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 9.7%
- Days to cover
- 10.0
- Shares short
- 1,525,798
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GYRE short interestGovernance
Frequently asked questions
What is the AI investment thesis for GYRE THERAPEUTICS, INC.?
GYRE THERAPEUTICS is a commercial-stage biopharmaceutical company focused on small-molecule therapies for organ fibrosis and inflammatory diseases, operating through a Chinese subsidiary and a U.S. headquarters, and recently acquired Cullgen to expand into targeted protein degradation.
What is GYRE THERAPEUTICS, INC.'s lead drug candidate?
GYRE THERAPEUTICS, INC.'s most advanced tracked candidate is avatrombopag (Approved) for Thrombocytopenia (TP) associated with chronic liver disease (CLD) and chronic idiopathic thrombocytopenia (ITP).
Who is the CEO of GYRE THERAPEUTICS, INC.?
Dr. Ying Luo Ph.D. is the chief executive officer of GYRE THERAPEUTICS, INC. (GYRE).
Where is GYRE THERAPEUTICS, INC. headquartered?
GYRE THERAPEUTICS, INC. (GYRE) is headquartered in San Diego, CA, United States.
What therapeutic areas does GYRE THERAPEUTICS, INC. focus on?
GYRE THERAPEUTICS, INC. develops therapies across Immunology, Cardiovascular, Respiratory, Hematology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.